-
In It for the Long HaulDoctors and researchers met online to discuss how the coronavirus pandemic changed cancer care in its early months, as well as how they can improve care and advocate for patients going forward.
by Kate Yandell
-
The Pandemic’s Impact on Cancer Screening and DetectionDelays in cancer screening and diagnosis due to the COVID-19 pandemic put people at risk.
by Kevin McLaughlin
-
From the Editor-in-Chief
Measuring a Cancer Drug’s EffectivenessSurrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?
by William G. Nelson, MD, PhD
-
Forward Look
Cancer Treatments and Antioxidant Supplements Can Be a Bad MixChristine Ambrosone on what her research shows.
by Sue Rochman
-
Forward Look
Here Come the BiosimilarsAs patents expire on biologic drugs, cancer patients get new options.
by Stephen Ornes
-
Forward Look
More Treatments Approved for Metastatic Breast CancerTargeted therapy approvals increase options and hope for some patients.
by Cameron Walker
-
Forward Look
Cancer Death Rate Decline Makes HeadlinesExperts say it's necessary to look behind the statistics.
by Delia O’Hara
-
-
Policy Matters
Racial and Ethnic Disparities in Multiple Myeloma Clinical TrialsThe AACR and the FDA presented joint recommendations that include broadening clinical trial eligibility and engaging the community in clinical trial recruitment.
by Kenneth C. Anderson, MD; Lola A. Fashoyin-Aje, MD, MPH; Nicole Gormley, MD; and Paul G. Kluetz, MD
-
Healthy Habits
One Drink, Too Many?Drinking at any level increases cancer risk.
by Ashley P. Taylor
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
